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Background: There are a few studies about paradoxical bronchodilator response (BDR), which means a 
decrease in forced expiratory volume in 1 second (FEV1) or forced vital capacity (FVC) after short-acting 
bronchodilator administration in patients with chronic obstructive pulmonary disease (COPD). We evaluated 
the effect of paradoxical BDR on the clinical outcomes of COPD patients in South Korea. 
Methods: We analyzed the KOrea COpd Subgroup Study team (KOCOSS) cohort data in South Korea 
between January 2012 and December 2017. BDR was defined as at least a 12% and 200-mL reduction in 
FEV1 or FVC after bronchodilator administration. 
Results: A total of 1,991 patients were included in this study. A paradoxical BDR was noted in 57 (2.9%) 
patients and was independently associated with worse dyspnea and poor quality of life. High C-reactive 
protein (CRP) levels were associated with a paradoxical BDR (OR, 1.05; 95% CI, 1.01–1.09; P=0.003). 
However, paradoxical BDR was not associated with severe acute exacerbations. Pre-bronchodilator FEV1 
(L) showed a higher area under the curve (AUC) for predicting severe acute exacerbations than the post-
bronchodilator FEV1 (L) in the paradoxical BDR group (0.788 vs. 0.752). 
Conclusion: A paradoxical reduction of FEV1 or FVC after bronchodilator administration may be 
associated with chronic inflammation in the airway and independently associated with worse respiratory 
symptoms and poor quality of life.
Keywords: Bronchodilator; chronic obstructive pulmonary disease (COPD); C-reactive protein (CRP); 
exacerbation; paradoxical
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Introduction
Post-bronchodilator spirometry is required for the 
diagnosis of chronic obstructive pulmonary disease (COPD), 
but the role of bronchodilator response (BDR) is unclear 
in COPD (1). Positive bronchodilator reversibility is no 
longer recommended as a treatment option for COPD, and 
there is no standard definition yet (2,3). In addition, positive 
bronchodilator reversibility does not predict the clinical 
outcomes of long-term use of bronchodilators and inhaled 
corticosteroid (ICS) (4). However, lung function may be 
paradoxically reduced after bronchodilator administration. 
In the previous study, COPD patients with paradoxical 
reductions in forced expiratory volume in 1 second 
(FEV1) or forced vital capacity (FVC) after bronchodilator 
spirometry had poor qualities of life and frequent severe 
exacerbations (5). The incorrect use of inhalers and 
bronchospasm in response to the ingredients in inhalers 
have been suggested, but the mechanism of paradoxical 
BDR is still unclear (6-8). To the best of our knowledge, 
no study has assessed paradoxical BDR and the clinical 
outcomes of COPD in an Asian population.
In this study, we aimed to evaluate the effect of 
paradoxical BDR on the clinical outcomes of COPD 
patients in the KOrea COpd Subgroup Study team 
(KOCOSS) cohort (NCT02800499).
Methods
Study design and patients
The KOCOSS cohort is an ongoing, longitudinal, 
prospective, non-interventional, and observational study 
within the South Korean patients with COPD. We 
recruited and analyzed cohort data between January 2012 
and December 2017. Inclusion criteria were as follows: age 
>40 years; symptoms including cough, sputum, and dyspnea; 
and post-bronchodilator FEV1/FVC <0.7. Exclusion criteria 
were as follows: asthma; inability to complete pulmonary 
function test; myocardial infarction or cerebrovascular 
event within the previous 3 months; pregnancy; rheumatoid 
arthritis; malignancy (metastatic cancer, leukemia, 
lymphoma); irritable bowel syndrome; and use of systemic 
steroids over 8 weeks for a reason other than COPD.
The protocol which was conducted according to the 
principle expressed in the Declaration of Helsinki was 
approved by the institutional review board (IRB) at each 
participating center (CNUH-2012-070). All patients 
provided written informed consent for participation in the 
study.
The initial evaluation for all patients included pulmonary 
function tests, 6-minute walk distance (6MWD), COPD 
Assessment Test (CAT), modified Medical Research 
Council (mMRC) dyspnea scale, COPD-specific version 
of St. George’s Respiratory Questionnaire (SGRQ-C), 
exacerbations in the previous 12 months, smoking status, 
medications, and comorbidities. Acute exacerbation of 
COPD was defined as the worsening of any respiratory 
symptom, including increased sputum volume, purulence, 
or increased dyspnea. Severe exacerbation was defined as 
the need for hospitalization or visiting the emergency room 
due to acute exacerbation of COPD.
Pulmonary function, disease severity, and exercise 
assessments
Spirometry and 6MWD were performed according to 
previous studies (9,10). COPD severity was categorized 
using spirometry alone, in accordance with the 2017 GOLD 
guidelines. Stage I COPD: FEV1 ≥80% predicted; stage 
II: FEV1 ≤50% to 80% predicted; stage III: FEV1 ≤30% 
to 50% predicted; and stage IV: FEV1 <30% predicted. 
The paradoxical BDR was defined as ≥12% and 200 mL 
reduction in FEV1 or FVC, respectively, or in both, after 
the administration of a bronchodilator, as described by 
previous reports and modified from the adapted American 
Thoracic Society criteria for BDR (11). The reduction in 
percentage was assessed as follows (5): 
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Descriptive statistics were reported as the mean and 
standard deviation for descriptive variables. For categorical 
variables, the number of patients per category and frequency 
of responses were recorded. Continuous variables with 
different severity classifications were analyzed using a two-
sample t-test and χ2 tests, and Fisher’s exact test was used for 
comparing categorical variables. Bivariate and multivariate 
linear regression models were used to assess the independent 
effects of paradoxical BDR status in the cohort in relation to 
mMRC, CAT, SGRQ-C, and 6MWD, with age, sex, body 
mass index (BMI), smoking burden, and pre-bronchodilator 
FEV1 as covariates. To identify the factors predictive of 
paradoxical BDR, the variables that differed significantly 
between the paradoxical BDR and no-paradoxical BDR 
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groups were included for univariate analysis with logistic 
regression. Subsequent multivariate logistic regression 
analysis using the backward method included variables 
with P<0.1 in the univariate analysis. Pre-bronchodilator 
and post-bronchodilator FEV1 (L) were assessed to predict 
acute severe exacerbations using the receiver operating 
characteristic curve and area under the curve (AUC) in 
paradoxical BDR groups. We evaluated the influence of 
paradoxical BDR on severe acute exacerbations by matching 
patients according to covariates of age, sex, current smoking 
status, BMI, pre-bronchodilator FEV1 (% predicted), 
CAT, SGRQ-C, comorbid diseases (heart disease, diabetes, 
hypertension, and previous 1-year acute exacerbation), and 
previously used inhalers [long-acting muscarinic antagonist 
(LAMA), long-acting β2-agonist (LABA), and ICS]. 
Propensity score matching was performed with 1:3 nearest 
neighbor matching without replacement. The caliper was 
0.05, and the absolute standardized differences of the mean 
were within 0.1 for all variables. Statistical analyses were 
performed using SPSS 23.0. Propensity score matching 
was performed using IBM SPSS 23.0 and R version R3.1.0 
(R Foundation for Statistical Computing, Vienna, Austria). 
P<0.05 was considered statistically significant.
Results
We enrolled 1,991 patients in this study from 2,279 patients 
recruited during the cohort period (Figure 1). Two hundred 
and eighty-eight patients were excluded; 82 patients 
recorded FEV1/FVC of >0.7 and 206 patients had missing 
FEV1 or FVC data at the time of enrollment.
We found 57 (2.9%) patients had a paradoxical BDR. 
Mean age was 68.8 years in the paradoxical BDR and 
69.2 years in the no-paradoxical BDR group (Table 1). 
The male sex was predominant representing 87.7% of the 
paradoxical BDR group and 90.8% of the no-paradoxical 
BDR group. There were no differences in underlying 
diseases between groups. Pre-bronchodilator FEV1 (L) 
was higher in the paradoxical BDR group than the no-
paradoxical BDR group. However, post-bronchodilator 
FEV1 and FVC were significantly higher in the no-
paradoxical BDR group than the paradoxical BDR group. 
A multivariate analysis that adjusted for age, sex, BMI, 
pack-years of smoking, and pre-bronchodilator FEV1 
(L), showed that the paradoxical BDR was independently 
associated with higher mMRC, CAT, and SGRQ-C scores 
(Table 2). 
To identify the factors predictive of paradoxical BDR, 
the variables that differed significantly between the two 
groups in Table 1 were selected; these were DLCO (% 
predicted), vital capacity, CRP, and pre-bronchodilator 
FEV1 (L). DLCO (% predicted), vital capacity, CRP, and pre-
bronchodilator FEV1 (L) were associated with paradoxical 
BDR in the univariate logistic regression analysis. However, 
multivariate logistic regression analysis using the backward 
method revealed that high CRP [odds ratio (OR), 1.05; 95% 
confidence interval (CI), 1.01–1.09; P=0.003] and DLCO (% 
predicted) (OR, 0.95; 95% CI, 0.92–0.98; P=0.004) were 
significantly associated with paradoxical BDR as shown in 
Table 3 (Nagelkerke R2 =0.218).
A paradoxical BDR was not associated with severe 
acute exacerbation during the 1-year period after logistic 
regression analysis with adjusting for confounding factors 
(Table 4). In addition, we used propensity score matching 
with variables to assess whether a paradoxical BDR was 
associated with severe acute exacerbation of COPD within 










Figure 1 Study flow chart. 
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Table 1 Baseline characteristics of the no-paradoxical and paradoxical BDR groups
Paradoxical BDR, (N=57) No-paradoxical BDR, (N=1,934) P value
Age, years 68.8±8.2 69.2±7.8 0.664
Sex, male 50 (87.7%) 1757 (90.8%) 0.274
Smoking history, pack-years 43.9±20.1 44.3±20.1 0.928
Current smokers 11 (20.0%) 512 (26.7%) 0.352
Body weight, kg 60.7±1.6 62.4±0.5 0.591
Height, meter 1.63±0.01 1.64±0.01 0.522
Body mass index, kg/m2 22.5±3.5 22.9±3.3 0.421
mMRC Score 1.3±0.9 1.4±0.9 0.733
CAT score 14.9±6.8 14.8±7.9 0.975
SGRQ-C total score 34.6±18.9 32.7±18.5 0.484
Heart disease 146 (7.5%) 6 (10.5%) 0.441
Diabetes mellitus 11 (19.6%) 313 (16.3%) 0.467
Hypertension 21 (37.5%) 747 (39.0%) 0.890
Pre-bronchodilator FEV1 
Value, L 2.25±2.50 1.53±0.55 0.035
Percent of predicted value, % 57.17±16.68 57.87±26.25 0.843
Pre-bronchodilator FVC
Value, L 3.18±0.88 3.12±0.80 0.582
Percent of predicted value, % 78.4±19.2 82.1±17.4 0.121
Pre-bronchodilator FEV1/FVC, % measure 53.6±15.5 49.0±11.8 0.006
Post-bronchodilator FEV1 
Value, L 1.41±0.62 1.62±0.56 0.005
Percent of predicted value, % 55.6±17.8 60.7±19.1 0.049
Post-bronchodilator FVC
Value, L 2.67±0.84 3.23±0.80 <0.000
Percent of predicted value, % 74.6±22.1 84.9±18.1 0.001
Post-bronchodilator FEV1/FVC, % measure 51.3±9.7 53.5±151.8 0.912
FEV1 change, mL –83.9±31.7 93.5±0.2 0.005
FEV1 change, % –25.3±4.0 6.9±0.2 <0.000
FVC change, mL –60.3±15.4 11.8±0.5 <0.000
FVC change, % –14.6±4.4 4.5±0.2 <0.000
DLCO 11.89±4.69 13.45±5.53 0.090
DLCO, % predicted 62.2±21.3 73.9±23.4 0.003
Total lung capacity, L 6.05±1.80 6.04±1.31 0.979
Table 1 (continued)
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Table 1 (continued)
Paradoxical BDR, (N=57) No-paradoxical BDR, (N=1,934) P value
Total lung capacity, % predicted 106.4±33.9 108.5±23.5 0.650
Vital capacity, L 2.92±0.77 3.27±0.79 0.030
Vital capacity, % predicted 79.2±16.7 92.2±45.6 0.154
Inspiratory capacity, L 2.22±1.15 1.84±0.60 0.135
Inspiratory capacity, % predicted 83.6±41.9 74.9±23.6 0.369
Functional residual capacity 84.05±0.95 4.15±1.19 0.695
Functional residual capacity, % predicted 124.5±27.2 129.2±42.6 0.605
Residual volume, L 2.85±1.15 2.77±2.07 0.857
Residual volume, % predicted 132.3±48.0 125.3±58.3 0.560
Residual volume/total lung capacity 48.3±15.9 44.6±14.4 0.255
GOLD stage
I 5 (8.8%) 281 (14.5%) 0.195
II 30 (52.6%) 1083 (56.0%)
III 17 (29.8%) 491 (25.4%)
IV 5 (8.8%) 79 (4.1%)
6MWD, meter 383.2±127.6 377.3±116.8 0.779
Eosinophil, % 3.23±3.59 3.35±3.41 0.818
C-reactive protein, mg/dL 11.6±18.2 2.7±7.5 0.055
Acute exacerbation
Acute exacerbations in prior year 16 (28.6%) 435 (22.8%) 0.333
Severe acute exacerbation in 1 year 5 (9.6%) 317 (23.5%) 1.000
Baseline drugs
Long-acting muscarinic antagonist 30 (52.6%) 1168 (60.4%) 0.272
Long-acting β2 agonist 25 (43.9%) 1,095 (56.6%) 0.059
Inhaled corticosteroid 20 (35.1%) 756 (39.1%) 0.584
Data are presented as number (%) or mean (SD). BDR, bronchodilator response; mMRC, modified Medical Research Council; CAT, COPD 
assessment test; SGRQ-C, COPD-specific version of St. George’s Respiratory Questionnaire; FEV1, forced expiratory volume in 1 second; 
L, liters; FVC, forced vital capacity; DLCO, diffusing capacity for carbon monoxide; GOLD, global initiative for chronic obstructive lung 
disease; 6MWD, 6-minute walk distance. Missing values [n]; smoking history [747], current smokers [20], body mass index [6], mMRC 
score [17], CAT score [77], SGRQ-C total score [46], diabetes mellitus [15], hypertension [19], DLco [393], total lung capacity [690], vital 
capacity [687], inspiratory capacity [848], functional residual capacity [777], residual volume [682], residual volume/total lung capacity [752], 
6MWD [493], eosinophil [394], C-reactive protein [1,074]. 
1 year. After 1:3 matching analysis, a paradoxical BDR was 
not associated with severe acute exacerbations of COPD.
The receiver operating characteristic curve predicting 
severe acute exacerbation during 1 year showed that pre-
bronchodilator FEV1 (L) had a higher AUC than post-
bronchodilator FEV1 (L) in the paradoxical BDR group 
(AUC, 0.788; 95% CI, 0.649–0.927; P=0.040 vs. AUC, 
0.752; 95% CI, 0.567–0.936; P=0.094, respectively).
Discussion
In this cohort study, we described the characteristics of 
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Table 2 Univariate and multivariate analysis of the paradoxical response and respiratory symptoms
Unadjusted Adjusted r2
β coefficient (95% CI) P value β coefficient (95% CI) P value
6-minute walk distance 0.149 
Age –3.80 (–4.55, –3.06) <0.000 –3.66 (–4.70, –2.62) <0.000
Sex, male 20.72 (–1.65, 43.11) 0.070 3.93 (–43.81, 51.68) 0.872
BMI 4.27 (2.49, 6.05) <0.000 2.95 (0.65, 5.24) 0.011
Pack-years –0.53 (–0.83, –0.23) 0.001 –0.39 (–0.68, –0.10) 0.008
FEV1 (L) 61.25 (51.09, 71.71) <0.000 49.33 (35.39, 63.27) <0.000
Paradoxical BDR 5.87 (–35.16, 46.91) 0.779 –20.39 (–40.72, –0.05) 0.951
Modified Medical Research Council score 0.109
Age 0.01 (0.01, 0.02) <0.000 0.01 (0.00, 0.02) <0.000
Sex, male –0.19 (–0.34, –0.04) 0.013 –0.04 (–0.37, 0.29) 0.814
BMI –0.02 (–0.03, -0.01) <0.000 –0.01 (–0.03, 0.00) 0.063
Pack-years 0.002 (0.000, 0.004) 0.014 0.002 (0.000, 0.004) 0.078
FEV1 (L) –0.41 (–0.47, –0.36) <0.000 –0.32 (–0.39, –0.25) <0.000
Paradoxical BDR –0.04 (–0.29, 0.20) 0.730 0.33 (0.02, 0.64) 0.034
COPD assessment test score 0.072
Age 0.04 (–0.00, 0.08) 0.084 0.02 (–0.04, 0.08) 0.564
Sex, male –1.50 (–2.84, –0.16) 0.028 –3.29 (–6.29, –0.29) 0.031
BMI –0.29 (–0.40, –0.19) <0.000 –0.25 (–0.39, –0.12) <0.000
Pack-years 0.02 (0.01, 0.04) 0.001 0.02 (0.01, 0.04) 0.002
FEV1 (L) –2.60 (–3.10, –2.11) <0.000 –2.03 (–2.63, –1.44) <0.000
Paradoxical BDR 0.03 (–0.29, 2.16) 0.975 2.85 (0.11, 5.58) 0.041
St. George’s Respiratory Questionnaire 0.176
Age 0.25 (0.14, 0.36) <0.000 0.05 (–0.08, 0.19) 0.466
Sex, male –3.43 (–6.58, –0.28) 0.033 –2.71 (–9.61, 3.78) 0.426
BMI –0.76 (–1.01, –0.51) <0.000 –0.28 (–0.59, 0.32) 0.079
Pack-years 0.04 (0.00, 0.08) 0.044 0.03 (–0.00, 0.06) 0.114
FEV1 (L) –12.61 (–13.99, –11.23) <0.000 –13.40 (–15.32, –11.47) <0.000
Paradoxical BDR 1.85 (–3.34, 7.05) 0.484 11.01 (4.71, 17.31) 0.001
BMI, body mass index; FEV1, forced expiratory volume in 1 second; L, liters; BDR, bronchodilator response; COPD, chronic obstructive 
pulmonary disease; CI, confidence interval.
patients with COPD who exhibit a paradoxically reduced 
FEV1 or FVC after bronchodilator administration. We 
found that the paradoxical BDR was independently 
associated with higher mMRC, CAT, and SGRQ-C 
scores, and an elevated CRP level was associated with 
paradoxical BDR after bronchodilator administration. Pre-
bronchodilator FEV1 (L) was more predictive of severe 
acute exacerbations of COPD than post-bronchodilator 
FEV1 (L) in the paradoxical BDR group.
We found that 57 (2.9%) of 1,991 patients with COPD 
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exhibited a paradoxical BDR, following the definition of 
a paradoxical BDR as described by a previous study (5). 
Previous studies have reported a paradoxical BDR incidence 
rate of 4% of all patients with COPD in the COPD Gene 
cohort. However, the ECLIPSE cohort reported that 47 
(2%) of 2493 patients showed a paradoxical BDR (5,12). In 
contrast, the UPLIFT cohort reported a very low incidence 
of 0.24%, wherein the paradoxical BDR was measured 
based on GOLD criteria (13). Racial differences may 
contribute to the differences in incidence of paradoxical 
BDR (5). In this Asian cohort study, the rate of paradoxical 
BDR was similar to the results of the ECLIPSE cohort. 
Further research is needed to determine whether racial 
differences influence the paradoxical BDR. 
The mechanisms associated with a paradoxical BDR 
after bronchodilator administration have not been fully 
elucidated. Several possible hypotheses include incorrect 
inhaler use, bronchospasm from the propellant or the 
benzalkonium chloride, chlorofluorocarbons, and oleic 
acid contained in inhalers (6-8). Population differences 
are observed in the paradoxical response, which might be 
associated with ß-receptor polymorphism (5). In this study, 
higher CRP expression was associated with the paradoxical 
BDR. Elevated CRP level is associated with reductions in 
FEV1 and worse outcomes in COPD (14,15). A smaller 
increase in FEV1 after administration of a bronchodilator 
is associated with elevated CRP levels in patients with 
COPD (16). CRP is associated with chronic respiratory 
inflammation in COPD; therefore, the deterioration 
of chronic inflammation may be associated with the 
paradoxical BDR to bronchodilator administration.
In this study, the paradoxical BDR was independently 
associated with worse dyspnea and a poorer quality of life. 
In line with this, Bhatt et al. reported that a paradoxical 
BDR was associated with lower 6MWD and higher 
mMRC scores (5). Emphysema and airway thickness are 
independently associated with airway obstruction in patients 
with COPD (17). Airway thickness but not emphysema 
Table 3 Predictive factors for a paradoxical bronchodilator response
Variables Odds ratio 95% CI P value
Univariate analysis
DLCO (% predicted) 0.97 0.96–0.99 0.003
Vital capacity 0.56 0.33–0.94 0.031
C-reactive protein 1.04 1.02–1.07 <0.000
Long-acting ß2 agonist 0.59 0.35–1.01 0.058
Pre-bronchodilator FEV1 (L) 3.07 2.00–4.72 <0.000
Multivariate analysis
C-reactive protein 1.05 1.01–1.09 0.003
DLCO (% predicted) 0.95 0.92–0.98 0.004
DLCO, diffusing capacity for carbon monoxide; FEV1, forced expiratory volume in 1 second; L, liters; CI, confidence interval.
Table 4 Predictive factors for severe 1-year acute exacerbation 
Variables Odds ratio 95% CI P value
Paradoxical BDR (crude) 0.49 0.19–1.27 0.145
Paradoxical BDRa 0.51 0.19–1.34 0.176
Paradoxical BDRb 0.51 0.19–1.37 0.187
Paradoxical BDR (propensity score matching analysis) 0.54 0.19–1.57 0.264
a, adjusted for age and sex; b, adjusted for age, male sex, CAT score, SGRQ-C score, and previous 1-year acute exacerbation. CI, 
confidence interval; BDR, bronchodilator response; CAT, COPD assessment test; SGRQ-C, COPD-specific version of St. George’s 
Respiratory Questionnaire.
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is significantly increased in the paradoxical BDR group 
(5). The increased airway thickness may have reduced the 
response to bronchodilators, consequently contributing to 
worse dyspnea and poor quality of life. However, paradoxical 
BDR was not associated with severe acute exacerbations in 
the present study. In contrast, Bhatt et al. reported that there 
was an increase in the frequency of severe exacerbation in 
a paradoxical BDR group after adjusting for confounding 
factors (5). Bhatt et al. explained that the incidence of severe 
acute exacerbation was increased in the paradoxical group 
because there were more African-Americans than whites 
in the paradoxical BDR group (5). African-Americans with 
COPD have poorer outcomes than whites (18). Considering 
racial differences, the present study suggests that Asian 
populations associated with paradoxical BDR are not prone 
to acute exacerbations of COPD. 
Post-bronchodilator FEV1 and FVC are key values in 
diagnosing COPD and assessing the prognosis. However, 
if the post-bronchodilator FEV1 is used for assessing 
the prognosis of COPD, airway obstruction can be 
overestimated. In this study, pre-bronchodilator FEV1 (L) 
is higher in the paradoxical BDR group than in the no-
paradoxical BDR group. However, post-bronchodilator 
FEV1 and FVC are significantly higher in the no-
paradoxical BDR group than in the paradoxical BDR group. 
We found that pre-bronchodilator FEV1 (L) had a higher 
AUC for predicting severe acute exacerbations than post-
bronchodilator FEV1 (L) in the paradoxical BDR group. 
While there was no difference between the pre-bronchodilator 
and post-bronchodilator FEV1 (% predicted) AUC at 
predicting severe acute exacerbations, pre-bronchodilator 
FEV1 measurements may be helpful in assessing disease 
prognosis in patients with a paradoxical BDR.
There are several limitations to this study. First, we 
did not assess the serial reversibility tests. Several studies 
showed that measurements are not consistent when 
repeated serial BDR tests are administered (19,20). Further 
study including analysis of the serial measurements is 
required. Second, there is no validated definition for 
paradoxical BDR; therefore, we used the definition from a 
previous study, which defined paradoxical BDR based on the 
American Thoracic Society criteria (5). Therefore, further 
studies are necessary to identify whether this definition 
yields meaningful results in other cohorts. Third, while we 
found that increased CRP was an independent factor to 
predict a paradoxical BDR in this study, we cannot exclude 
the influence of other chronic inflammatory conditions. 
To reduce this influence, we adjusted for other chronic 
inflammatory diseases, such as heart disease, diabetes 
mellitus, and hypertension. After adjusting for these 
variables, higher CRP was significantly associated with a 
paradoxical BDR (OR, 1.06; 95% CI, 1.02–1.10; P=0.001). 
Fourth, although patients with asthma were excluded, 
some of them may have been included among patients with 
positive bronchodilator reversibility. It is also possible that 
these patients underused ICS.
Conclusions
A paradox i ca l  r educ t ion  o f  FEV 1 or  FVC a f t e r 
bronchodilator administration is independently associated 
with worse respiratory symptoms and a poor quality of 
life in patients with COPD and may be associated with 
chronic inflammation in the airway. While paradoxical 
BDR was not associated with severe acute exacerbations, 
pre-bronchodilator FEV1 (L) may be a useful measure 
for predicting severe acute exacerbations in patients with 
paradoxical BDR.
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